ATE517182T1 - Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese - Google Patents

Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese

Info

Publication number
ATE517182T1
ATE517182T1 AT07003963T AT07003963T ATE517182T1 AT E517182 T1 ATE517182 T1 AT E517182T1 AT 07003963 T AT07003963 T AT 07003963T AT 07003963 T AT07003963 T AT 07003963T AT E517182 T1 ATE517182 T1 AT E517182T1
Authority
AT
Austria
Prior art keywords
kilodaltons
amino acid
molecule
endothelial inhibitor
angiostatin
Prior art date
Application number
AT07003963T
Other languages
English (en)
Inventor
Michael S O'reilly
Judah M Folkman
Kim Lee Sim
Yihai Cao
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22939956&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE517182(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Application granted granted Critical
Publication of ATE517182T1 publication Critical patent/ATE517182T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07003963T 1994-04-26 1995-04-26 Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese ATE517182T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/248,629 US5639725A (en) 1994-04-26 1994-04-26 Angiostatin protein
US08/326,785 US5792845A (en) 1994-04-26 1994-10-20 Nucleotides encoding angiostatin protein and method of use

Publications (1)

Publication Number Publication Date
ATE517182T1 true ATE517182T1 (de) 2011-08-15

Family

ID=22939956

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07003963T ATE517182T1 (de) 1994-04-26 1995-04-26 Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese

Country Status (8)

Country Link
US (4) US5639725A (de)
EP (1) EP1783215B1 (de)
KR (1) KR100336452B1 (de)
AT (1) ATE517182T1 (de)
DK (1) DK1783215T3 (de)
ES (1) ES2370155T3 (de)
PT (1) PT1783215E (de)
ZA (1) ZA953419B (de)

Families Citing this family (213)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248799A1 (en) * 1993-05-27 2004-12-09 Holaday John W. Compositions and methods for treating cancer and hyperproliferative disorders
ES2204919T3 (es) * 1993-05-27 2004-05-01 Entremed, Inc. Composiciones y procedimientos de tratamiento del cancer y de enfermedades hiperproliferativas.
US6805865B1 (en) 1993-05-27 2004-10-19 Entremed, Inc. Compositions and methods for treating cancer and hyperproliferative disorders
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US20010055581A1 (en) 1994-03-18 2001-12-27 Lawrence Tamarkin Composition and method for delivery of biologically-active factors
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5945403A (en) * 1997-05-30 1999-08-31 The Children's Medical Center Corporation Angiostatin fragments and method of use
US6949511B1 (en) 1994-04-26 2005-09-27 The Children's Medical Center Corporation Methods of inhibiting angiogenesis via increasing in vivo concentrations of kringle region fragments of plasminogen
US20040265288A1 (en) * 1995-03-08 2004-12-30 Gilman Michael Z. New applications of gene therapy technology
JP3840262B2 (ja) * 1995-10-23 2006-11-01 ザ チルドレンズ メディカル センター コーポレイション 治療用の抗血管新生組成物および方法
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
US5801146A (en) * 1996-05-03 1998-09-01 Abbott Laboratories Compound and method for inhibiting angiogenesis
CA2255865C (en) * 1996-05-24 2008-10-14 The Regents Of The University Of Minnesota Synthesis of soluble beta-sheet forming peptides
US6080728A (en) * 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
US5700821A (en) * 1996-07-30 1997-12-23 University Of Pittsburgh Phosphatase inhibitors and methods of use thereof
US5801012A (en) * 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
US6593291B1 (en) 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
AU6578298A (en) 1997-03-21 1998-10-20 President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
US7220557B2 (en) * 1997-04-24 2007-05-22 Human Genome Sciences, Inc. METH1 polynucleotides
WO1998049321A2 (en) * 1997-04-28 1998-11-05 Rhone-Poulenc Rorer S.A. Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors
JP2001511462A (ja) * 1997-07-31 2001-08-14 セント エリザベス メディカル センター オブ ボストン インク． 移植片処置法
WO1999009982A1 (en) * 1997-08-25 1999-03-04 Harold Brem Prevention of adhesions and excessive scar formation using angiogenesis inhibitors
US20020002294A1 (en) * 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
US6306819B1 (en) 1997-10-31 2001-10-23 Massachusetts Institute Of Technology Method for regulating size of vascularized normal tissue
US6407218B1 (en) * 1997-11-10 2002-06-18 Cytimmune Sciences, Inc. Method and compositions for enhancing immune response and for the production of in vitro mabs
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
WO1999026480A1 (en) * 1997-11-20 1999-06-03 Genetix Pharmaceuticals, Inc. Anti-angiogenic gene therapy vectors and their use in treating angiogenesis-related diseases
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
AU3980499A (en) 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
US20040022788A1 (en) 1998-05-19 2004-02-05 Moser Tammy L. Compositions and methods for promoting or inhibiting angiogenesis
WO1999059620A1 (en) * 1998-05-19 1999-11-25 Duke University Angiostatin receptor
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US20030012792A1 (en) * 1998-05-22 2003-01-16 Holaday John W. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
AU762615B2 (en) * 1998-06-15 2003-07-03 Arch Development Corporation Combination of radiotherapy and anti-angiogenic factors
WO2000001410A1 (en) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
IL140729A0 (en) * 1998-07-14 2002-02-10 Bristol Myers Squibb Co Lysine binding fragments of angiostatin, pharmaceutical compositions containing the same and processes for the preparation thereof
WO2000010506A2 (en) * 1998-08-20 2000-03-02 University Of Vermont And State Agriculture College Angiogenesis inhibitors and uses thereof
US6949081B1 (en) 1998-08-26 2005-09-27 Non-Invasive Technology, Inc. Sensing and interactive drug delivery
SI1107795T1 (en) 1998-09-04 2003-06-30 The Regents Of The University Of Michigan Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis
US6200954B1 (en) 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US7317003B2 (en) * 1998-09-04 2008-01-08 National University Of Singapore Small peptides having anti-angiogenic and endothelial cell inhibition activity
US6537554B1 (en) 1998-09-10 2003-03-25 Curagen Corporation Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US6248327B1 (en) 1998-09-11 2001-06-19 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US7176289B1 (en) 1998-09-11 2007-02-13 Vanderbilt University Modulation of endothelial cell surface receptor activity in the regulation of angiogenesis
US6596690B2 (en) * 1998-10-06 2003-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vasostatin as marrow protectant
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US6218361B1 (en) 1998-11-18 2001-04-17 Children's Medical Center Corporation Treatment of chronic allograft rejection with anti-angiogenic agents
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
DE60034434T2 (de) * 1999-02-10 2008-01-10 The Children's Medical Center Corp., Boston Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren
US6465424B1 (en) 1999-02-17 2002-10-15 Bristol-Myers Squibb Company Anti-angiogenic agent and method for inhibiting angiogenesis
US6420345B1 (en) 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
AU3755900A (en) * 1999-03-15 2000-10-04 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US8383081B2 (en) 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US8119101B2 (en) * 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
BR0010750A (pt) * 1999-05-17 2002-02-26 Conjuchem Inc Peptìdeos insulinotrópicos de longa duração
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
NZ516237A (en) * 1999-05-25 2004-03-26 Human Genome Sciences Inc Meth1 and meth2 polynucleotides and polypeptides
US6890904B1 (en) 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) * 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
CA2384929C (en) 1999-09-15 2006-12-05 Mogam Biotechnology Research Institute A novel angiogenesis inhibitor
US20080241835A1 (en) * 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
EP1227843B1 (de) 1999-11-10 2009-10-14 BioPheresis Technologies, Inc. Verfahren und system zur entfernung von zytokininhibitoren in patienten
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
EP1218495A2 (de) * 1999-12-03 2002-07-03 EntreMed, Inc. Methode zur herstellung und reinigung von angiostatin-m(3)
US6723536B2 (en) 1999-12-03 2004-04-20 Entremed, Inc. Method of producing and purifying angiostatin
US6380253B1 (en) 2000-01-05 2002-04-30 Efa Sciences Llc Method of stabilizing and potentiating the action of anti-angiogenic substances
WO2001058240A2 (en) * 2000-02-10 2001-08-16 Massachusetts Eye And Ear Infirmary Photodynamic therapy for treating conditions of the eye
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
CA2400403C (en) * 2000-02-18 2011-07-19 New York Medical College 1-nitroacridine/tumor inhibitor compositions
US6825167B1 (en) 2000-04-03 2004-11-30 Regents Of The University Of Minnesota Genetic modification of endostatin
KR20030064275A (ko) * 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US7135581B2 (en) * 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
ES2272537T3 (es) * 2000-09-01 2007-05-01 Philadelphia, Health And Education Corporation Metodos y composiciones para inhibir la angiogenesis.
US7160858B2 (en) * 2000-09-01 2007-01-09 Philadelphia, Health And Education Corporation Methods and compositions for inhibiting angiogenesis
AU8591901A (en) 2000-09-05 2002-03-22 Karolinska Innovations Ab Materials and methods relating to endothelial cell growth inhibitors
US20030104573A1 (en) * 2000-09-11 2003-06-05 Shimkets Richard A. Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis
US20020159992A1 (en) * 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
AU2002239366A1 (en) 2000-11-28 2002-06-11 Geetha Kassam Anti-angiogenic polypeptides
ATE374609T1 (de) * 2000-11-30 2007-10-15 Childrens Medical Center Synthese von 4-aminothalidomid enantiomeren
US20040121945A1 (en) * 2000-12-15 2004-06-24 Hong Liang Compositions and methods for inhibiting endothelial cell proliferation
WO2002053191A1 (en) * 2001-01-05 2002-07-11 Viromed Limited Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
RU2003129528A (ru) * 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (de) 2001-05-03 2011-03-16 Merck Patent GmbH Rekombinanter, tumorspezifischer antikörper und dessen verwendung
AU2002346611A1 (en) * 2001-12-03 2003-06-17 The Regents Of The University Of California Expression of glial-derived neurotrophic factor for treatment of diseases of the eye
DK1454138T3 (da) * 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
PT3025726T (pt) 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
WO2003063787A2 (en) * 2002-01-30 2003-08-07 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
US7255986B2 (en) * 2002-01-31 2007-08-14 The Board Of Trustees Operating Michigan State University Compositions for the diagnosis and treatment of epizootic catarrhal enteritis in ferrets
AU2003211163A1 (en) 2002-02-20 2003-09-09 Regents Of The University Of Minnesota Partial peptide mimetics and methods
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
EP1572078A4 (de) * 2002-03-08 2006-08-09 Univ Emory NEUE CURCUMINOID-FAKTOR-VIIa-KONSTRUKTE ALS MITTEL ZUR UNTERDRÜCKUNG VON TUMORWACHSTUM UND ANGIOGENESE
US7285277B2 (en) * 2002-03-15 2007-10-23 Mogam Biotechnology Research Institute Anticancer agent
EP1539799B1 (de) * 2002-06-21 2013-12-11 The University of Utah Research Foundation Quervernetzte verbindungen und verfahren zu deren herstellung und anwendung
WO2004002418A2 (en) * 2002-06-26 2004-01-08 Entremed, Inc Compositions and methods comprising protein activated receptor antagonists
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
GEP20074270B (en) 2002-07-23 2007-12-25 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
US8071569B2 (en) * 2002-09-20 2011-12-06 Mousa Shaker A Oxidized heparin fractions and their use in inhibiting angiogenesis
US20030153013A1 (en) * 2002-11-07 2003-08-14 Ruo-Pan Huang Antibody-based protein array system
MXPA05005545A (es) * 2002-11-25 2005-10-18 Attenuon Llc Peptidos que se dirigen a celulas tomurales y endoteliales, composiciones y usos de los mismos.
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
EP1581164A4 (de) * 2002-12-13 2008-03-12 Mediomics Llc Zusammensetzungen und verfahren zur hemmungvon tumorwachstum und metastasen
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
WO2004093892A2 (en) * 2003-04-16 2004-11-04 Genentech, Inc. Stanniocalcin-1, variant or antagonists thereof for selective modulation of vascularization
CN101137388A (zh) 2003-05-15 2008-03-05 犹他卅大学研究基金会 抗粘连复合材料及其应用方法
JP2007516234A (ja) * 2003-05-27 2007-06-21 アテニュオン，リミティド ライアビリティー カンパニー チオタングステン酸（塩）アナログ及びその使用
EP1633367A2 (de) * 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogene mittel
WO2004113361A2 (en) * 2003-06-20 2004-12-29 The Regents Of The University Of California Novel prokineticin receptor isoforms and methods of use
WO2005007193A2 (en) * 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
US20050143300A1 (en) * 2003-10-10 2005-06-30 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050250694A1 (en) * 2003-10-10 2005-11-10 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
US20050175583A1 (en) * 2003-12-02 2005-08-11 Lawrence Tamarkin Methods and compositions for the production of monoclonal antibodies
EP1694712A1 (de) 2003-12-04 2006-08-30 University of Utah Research Foundation Modifizierte makromoleküle und verfahren zu ihrer herstellung und verwendung
US20100330143A1 (en) 2003-12-04 2010-12-30 University Of Utah Research Foundation Modified macromolecules and methods of making and using thereof
US20050130897A1 (en) * 2003-12-11 2005-06-16 Ma Jian-Xing Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
EP1715971A4 (de) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc Funktionalisierte kolloidale metallzusammensetzungen und verfahren
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
WO2005082382A1 (en) * 2004-02-23 2005-09-09 Attenuon Llc Formulations of thiomolybdate or thiotungstate compounds and uses thereof
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
CA2558014A1 (en) * 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
AU2005236075A1 (en) * 2004-04-26 2005-11-03 Children's Medical Center Corporation Platelet biomarkers for the detection of disease
JP2008511340A (ja) * 2004-04-30 2008-04-17 バイオフェレシス テクノロジーズ， インコーポレイテッド 患者において可溶性ｔｎｆｒ１、可溶性ｔｎｆｒ２、および可溶性ｉｌ２を除去する方法およびシステム
US8618054B2 (en) * 2004-05-05 2013-12-31 Valorisation-Rechereche Société en Commandite Interleukin-1 receptor antagonists, compositions, and methods of treatment
JP2008510726A (ja) * 2004-08-20 2008-04-10 エントレメッド インコーポレイテッド プロテイナーゼ活性化受容体アンタゴニストを含む組成物および方法
MX2007006214A (es) * 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.
JP2008521822A (ja) * 2004-11-29 2008-06-26 エントレメッド インコーポレイテッド 抗血管形成剤を投与する方法、およびそれを用いて疾病を治療する方法
WO2006084016A1 (en) 2005-02-01 2006-08-10 Attenuon, Llc ACID ADDITION SALTS OF Ac-PHSCN-NH2
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
WO2007004060A2 (en) 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
CA2646065C (en) * 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
US20100285094A1 (en) * 2006-04-20 2010-11-11 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US8747870B2 (en) 2006-04-20 2014-06-10 University Of Utah Research Foundation Polymeric compositions and methods of making and using thereof
US20080032920A1 (en) * 2006-07-11 2008-02-07 Prestwich Glenn D Macromolecules modified with electrophilic groups and methods of making and using thereof
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
US20080287341A1 (en) * 2007-05-18 2008-11-20 Danyang Chen Treatment of vascular abnormalities using nanoparticles
KR20100123674A (ko) * 2007-09-21 2010-11-24 싸이티뮨 사이언스, 인크. 나노치료제 콜로이드성 금속 조성물 및 방법
US20110014118A1 (en) * 2007-09-21 2011-01-20 Lawrence Tamarkin Nanotherapeutic colloidal metal compositions and methods
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
EP2352817B1 (de) 2008-10-31 2016-01-27 University Of Louisville Research Foundation, Inc. Stammzellen aus der riechschleimhaut und ihre verwendung
EP2523680A4 (de) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology Verstärkte zytotoxizität von antikörpern gegen cd74 und hla-dr mit interferon-gamma
CA2795698A1 (en) * 2010-03-05 2011-09-09 Angstrom Pharmaceuticals, Inc. Modulation of intracellular signaling
US10865383B2 (en) 2011-07-12 2020-12-15 Lineage Cell Therapeutics, Inc. Methods and formulations for orthopedic cell therapy
US8921533B2 (en) 2011-07-25 2014-12-30 Chromatin Technologies Glycosylated valproic acid analogs and uses thereof
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
WO2013085893A1 (en) 2011-12-05 2013-06-13 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
EP2628748A1 (de) 2012-02-14 2013-08-21 Szilak Laboratories Bioinformatics & Molecule-Design Ltd. Angiostatin-Chimäre und deren Verwendungen
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US20240139324A1 (en) 2012-12-13 2024-05-02 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
CN107753954A (zh) 2012-12-13 2018-03-06 免疫医疗公司 功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US12310958B2 (en) 2012-12-13 2025-05-27 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
WO2015012904A2 (en) 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
JP2016507307A (ja) 2013-02-13 2016-03-10 カルティヒール（２００９）リミティド 細胞及び組織の付着及び血管新生の軽減又は予防のための固体基材
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10064940B2 (en) 2013-12-11 2018-09-04 Siva Therapeutics Inc. Multifunctional radiation delivery apparatus and method
EP3800191B1 (de) 2014-03-17 2025-08-20 Adverum Biotechnologies, Inc. Zusammensetzungen und verfahren zur verbesserten genexpression in zapfenzellen
US11021519B2 (en) 2015-03-02 2021-06-01 Adverum Biotechnologies, Inc. Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
AU2016252771B2 (en) 2015-04-22 2021-12-16 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells
WO2016205010A1 (en) * 2015-06-19 2016-12-22 The Regents Of The University Of California Treating vasculature related diseases or disorders using nanoparticles
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
AU2017257254B2 (en) 2016-04-27 2022-02-24 Immunomedics, Inc. Efficacy of anti-Trop-2-SN-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
EP3600283A4 (de) 2017-03-27 2020-12-16 Immunomedics, Inc. Behandlung von trop-2-exprimierendem triple-negativem brustkrebs mit sacituzumab govitecan und einem rad51-hemmer
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy
IL317026A (en) 2018-02-28 2025-01-01 Plas Free Ltd In vitro device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
EP4121018A4 (de) 2020-03-17 2024-07-03 Genevant Sciences Gmbh Kationische lipide zur lipidnanopartikelabgabe von therapeutika an hepatische stellatzellen
TWI910217B (zh) * 2020-08-20 2026-01-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療腫瘤的方法和藥物
AU2021403156A1 (en) 2020-12-18 2023-07-13 Genevant Sciences Gmbh Peg lipids and lipid nanoparticles
KR20240146674A (ko) 2022-01-31 2024-10-08 제네반트 사이언시즈 게엠베하 지질 나노입자를 위한 이온화 가능한 양이온성 지질
WO2025052278A1 (en) 2023-09-05 2025-03-13 Genevant Sciences Gmbh Pyrrolidine based cationic lipids for lipid nanoparticle delivery of therapeutics to hepatic stellate cells
WO2025133951A1 (en) 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
WO2026022656A2 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Lipid particle formulations with permanently charged cationic lipids
WO2026022677A1 (en) 2024-07-22 2026-01-29 Genevant Sciences Gmbh Permanently charged cationic lipids

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192744A (en) * 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors

Also Published As

Publication number Publication date
KR100336452B1 (ko) 2002-12-26
EP1783215B1 (de) 2011-07-20
US5792845A (en) 1998-08-11
US5733876A (en) 1998-03-31
US5639725A (en) 1997-06-17
DK1783215T3 (da) 2011-10-31
EP1783215A1 (de) 2007-05-09
PT1783215E (pt) 2011-10-31
ZA953419B (en) 1996-01-11
ES2370155T3 (es) 2011-12-13
US5776704A (en) 1998-07-07

Similar Documents

Publication Publication Date Title
ATE517182T1 (de) Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
ATE355379T1 (de) Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
Soliday et al. Cloning and structure determination of cDNA for cutinase, an enzyme involved in fungal penetration of plants
RU95110871A (ru) Способы определения нуклеотидной последовательности
PT741515E (pt) Traducao transgenica de anticorpos no leite
CY2007027I2 (el) ΑΜΙΔΙΑ δ-ΑΜΙΝΟ-γ-ΥΔΡΟΞΥ-ω-ΑΡΥΛΟ-ΑΛΚΑΝΙΚΟΥ ΟΞΕΟΣ ΜΕ ΙΔΙΟΤΗΤΕΣ ΑΝΑΣΤΟΛΗΣ ΕΝΖΥΜΩΝ, ΙΔΙΑΙΤΕΡΑ ΤΗΣ ΡΕΝΙΝΗΣ
YU8997A (sh) Prečišćen protein koji ima serinsku proteaznu inhibitorsku aktivnost i farmaceutski preparat koji ga sadrži
EP0921818A4 (de) Therapeutische und diagnostische verfahren und zusammensetzungenauf der basis von jagged/notch-proteinen und aminosäuren
FI942625A7 (fi) Peptidisiä fosfinyylioksimetyyliketoneja interleukiini-1beta-muuttuvan entsyymin inhibiittoreina
DK430486A (da) Fremgangsmaade til udvinding af protein
EP0205475A4 (de) Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu.
ATE389023T1 (de) Kontrolle der schotendehiszenz
DE69433357D1 (de) Rekombinantes Mersacidin und Verfahren zu seiner Herstellung
DE59914580D1 (de) Verfahren zur chromatographischen reinigung von insulinen
DE69405329D1 (de) Reinigung von 2-Methylglutaro- oder Adiponitril
WO1998003652A3 (en) P300/cbp-associated transcriptional co-factor p/caf and uses thereof
ATE333469T1 (de) Verfahren zur reinigung hochanionischer proteine
Shigeta et al. Fragmentation of a 70000-dalton calpastatin molecule upon its complex formation with calpain
ATE237636T1 (de) Reinigung von molekülen
ATE432349T1 (de) Modifizierte hämoglobinähnliche verbindungen und verfahren zu deren reinigung
Dalet-Fumeron et al. High-performance liquid chromatographic method for the simultaneous purification of cathepsins B, H and L from human liver
DE69609815D1 (de) Verfahren zur reinigung von pentafluorethan
ATE57471T1 (de) Im blut identifiziertes protein, ein verfahren zu seiner zubereitung, ein verfahren fuer die bestimmung dieses proteins und ebenfalls des t-pa-hemmungsfaktors und pharmazeutische zusammensetzungen, die dieses protein enthalten.
FI946031L (fi) Kringleä sisältävien proteiinien puhdistus ja etenkin t-PA:n
US5700365A (en) Crosslinked polyacrylamide gels with high monomer: crosslinker ratios

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1783215

Country of ref document: EP